Session » Muscle Biology, Myositis & Myopathies Poster

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1091

A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD

9:00AM-11:00AM: Abstract Number: 1074

A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine

9:00AM-11:00AM: Abstract Number: 1090

Abnormal HDL Antioxidant Function Is Associated with Longitudinal Change in Lung Physiology in Dermatomyositis/Polymyositis Associated Lung Disease

9:00AM-11:00AM: Abstract Number: 1083

Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment

9:00AM-11:00AM: Abstract Number: 1073

Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1098

Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 1076

Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom

9:00AM-11:00AM: Abstract Number: 1059

Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Features of More Severe Disease in Adult-onset Myositis

9:00AM-11:00AM: Abstract Number: 1064

Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis

9:00AM-11:00AM: Abstract Number: 1067

Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1096

Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 1095

Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1060

B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 1071

Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore

9:00AM-11:00AM: Abstract Number: 1084

Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis Patients

9:00AM-11:00AM: Abstract Number: 1061

Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers

9:00AM-11:00AM: Abstract Number: 1062

Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 1056

Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement

9:00AM-11:00AM: Abstract Number: 1075

Diagnostic Utility of Myositis Antibodies in HyperCKemia: A University Affiliated Single Center Retrospective Study

9:00AM-11:00AM: Abstract Number: 1057

Earlier Cancer Diagnosis After Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival – Results from Four European Cohorts

9:00AM-11:00AM: Abstract Number: 1068

Efficacy of Early Initiation of Plasma Exchange Therapy for a Patient with Anti-MDA5 Autoantibody-Positive Dermatomyositis Developing Refractory Rapidly Progressive Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1077

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis

9:00AM-11:00AM: Abstract Number: 1099

High Burden of Infections in Indian Patients with Idiopathic Inflammatory Myopathy: Validation of Observations from the MyoCite Dataset

9:00AM-11:00AM: Abstract Number: 1078

Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis

9:00AM-11:00AM: Abstract Number: 1097

Immunophenotypic Characterization of Myeloid Derived Supressor Cells (MDSCs) and Their Relationship to the Clinical Characteristics of Patients with Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1065

Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1093

Impact of Blood Flow Restricted Strength Training on Myogenic Stem Cells and Myofiber Hypertrophy in Sporadic Inclusion Body Myositis Patients

9:00AM-11:00AM: Abstract Number: 1089

Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1094

Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1092

NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?

9:00AM-11:00AM: Abstract Number: 1085

Pain in Myositis Is Associated with the Disease Activity

9:00AM-11:00AM: Abstract Number: 1081

Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1087

Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1066

Prevalence of Cervical Dysplasia in Women with Antisynthetase Syndrome

9:00AM-11:00AM: Abstract Number: 1088

Recruitment Rates of Virtual Remote Research (Tele-Research) in Myositis

9:00AM-11:00AM: Abstract Number: 1070

Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features

9:00AM-11:00AM: Abstract Number: 1069

Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy

9:00AM-11:00AM: Abstract Number: 1080

Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America

9:00AM-11:00AM: Abstract Number: 1079

Sex Differences in Antibody Profile, Phenotype, and Treatment Response in a Racially Diverse Population with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1072

Sexual Health Impairment in 62 Female Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1063

Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro

9:00AM-11:00AM: Abstract Number: 1086

The Diagnostic Value and Clinical Significance of Myositis-Specific Antibodies in Patients Suspected to Have Autoimmune Myopathies and/or Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1082

The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect

9:00AM-11:00AM: Abstract Number: 1058

The Relationship of Different Muscle Enzymes in Adult Myositis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].